La asociación de la menstruación de pacientes con cáncer de mama con el régimen de quimioterapia y el período de envejecimiento

OBJECTIVE:

We aimed to study the influence of chemotherapeutic regimens and aging of breast cancer patients on chemotherapy-induced amenorrhea(CIA) and to guide the further selection of drugs for endocrine therapy.

METHODS:

We retrospectively studied the chemotherapy-induced amenorrhea(CIA) of the premenopausal breast cancer patients and compare the difference in CIA between the patients who received different chemotherapies or at different aging periods.

RESULTS:

One hundred and three women were followed up.The difference in the rate of CIA was not statistically significant between the women who received anthracycline-based chemotherapy and docetaxel-based chemotherapy(70.6% vs 61.1%,P=0.719).The occurrence rate of CIA was significantly higher in older women(45 years) than young women(≤45 years,P0.001).CIA occurred more lately in young women than old women(P=0.001).

CONCLUSION:

Age is an important factor for the CIA.Chemotherapy has less influence on the menstruation of younger women(≤45 years) and most amenorrhea is reversible.For these patients aromatase inhibitors are not recommended for adjuvant endocrine therapy.The effect of docetaxel on menstruation is not greater than anthracycline.